AC
KYMR icon

Athanor Capital’s Kymera Therapeutics KYMR Stock Holding History

Athanor Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,409
Closed -$249K – 613
2021
Q1 		$249K Sell
6,409
-13,083
-67% -$787K 0.01% 629
2020
Q4 		$1.21M Buy
19,492
+9,852
+102% +$481K 0.03% 266
2020
Q3 		$311K Buy
+9,640
New +$294K 0.01% 416

Other funds holding KYMR

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DIC
Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Athanor Capital's KYMR Position: Q2 2021 in Review

Athanor Capital sold out of Kymera Therapeutics (KYMR) in Q2 2021, closing a stake of 6,409 shares — an estimated $249K sold.

Athanor Capital first reported a position in KYMR in Q3 2020 and held it in 3 quarters. The position peaked at $1.21M in Q4 2020. 110 funds tracked by Wall St. Rank hold KYMR as of Q2 2021.

  • Athanor Capital reported no remaining Kymera Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 6,409 Kymera Therapeutics shares in Q2 2021, an estimated $249K.
  • Athanor Capital first reported a position in Kymera Therapeutics in Q3 2020 and held it in 3 quarters.
  • Athanor Capital's Kymera Therapeutics position peaked at $1.21M in Q4 2020.
  • 110 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.